123ArticleOnline Logo
Welcome to 123ArticleOnline.com!

ALL >> Business >> View Article

Harver Group Targets Biotech Bull

By Author: Harver Group
Total Articles: 26

Jul. 24, 2013 - CHUO-KU, Japan -- Due to the huge increase in staff and board members buying stock in Synta Pharmaceuticals, and the successful trials of Synta Pharmaceuticals latest cancer drug Ganetespib, Pharmaceutical Analysts at Harver Group are now strongly recommending the stock as a buy to investors.

Stephen James, Director of Private Equity at Harver Group in Tokyo, commented “A huge indicator for me that a stock is about to take off is insider buying. We have seen quite a bit of this over the past few weeks at Synta Pharmaceuticals, Hedge Fund Manager, Bruce Kovner who has also been on the board of directors since 2002, has bought 3 million shares for just over $13 million. President and CEO Safi Bachall also bought 10,000 shares bring his total to almost 2 million.”

Synta Pharmaceuticals (SNTA) is a biopharmaceutical corporation which creates, develops, and commercializes drugs that extend and increase the standard of living of patients with cancer and other chronic diseases. The Company has a unique library of propriety chemical compounds acquired over two decades from academic and industrial sources. These compounds are optimized through a variety of techniques to create new drug candidates.

Their most exciting new drug candidate is called Ganetespib and is used to treat lung, breast, colorectal, and hemolytic cancer. Ganetespib is a small molecular inhibitor of heat shock protein 90 (Hsp90) which is required for the maturation and activation of a number of proteins. Cancer cells thrive in the presence of Hsp90, inhibiting it can greatly reduce tumors proliferation. The drug has been tested on over 700 patients in 20 clinical trials. Although trials are not finished and the company has not released a full report, the drug has shown a lot of promise.

Nathan Marx, Head of Investment Analysis said, “Although their share price has dropped from its $10 a share high in April, I expect it to return to this price in the next three months and I am recommending my clients to buy.” Peter Anderson, Senior Vice President of Mergers and Acquisitions at Harver Group said

“This is an exciting company, on the verge of a major breakthrough, displaying all the signs of a strong financial instrument for these coming quarters, so I’m confident our clients will see growth in this area”.

Total Views: 1225Word Count: 382See All articles From Author

Business Articles

1. Five Things You Could Be Doing Wrong While Choosing Your Renovations Team
Author: Stephen Kavita

2. Add Value To Your Lancaster Home With The Right Renovations & Remodeling
Author: Cory Frank

3. Get The Most Out Of Family Counseling
Author: Cory Frank

4. The Case For Composite Decking
Author: Blue Star Carpentry

5. Motivation & Support
Author: EnemarkFitness.Lu

6. What Is A Leased Line And Its Advantages
Author: Ketan Shah

7. Carpet Cleaning And Flood Damage Repair
Author: Irvinecarpetcleaningmain

8. General Description About Bolts
Author: Harpreet Chhabra

9. Garage Door Service Irvine
Author: fastergaragedoors

10. Carpet Cleaning In Tustin
Author: gfcmain1

11. Colorado Garage Door Company
Author: broncogaragedoorservice

12. Hollywood Hills Carpet Cleaners
Author: Socalcarpetcleaning1

13. Custom Home Bars Make The Perfect Spot For Your Home Parties
Author: Larry Lynch

14. Overview On Benefits Of Telco Cost Saving To Benchmark Your Business
Author: Amber Brake

15. Corona Del Mar Carpet Cleaning
Author: greenfloorcaremain

Login To Account
Login Email:
Password:
Forgot Password?
New User?
Sign Up Newsletter
Email Address: